Next Article in Journal
Integrated Transcriptomic, Proteomic, and Metabolomics Analysis Reveals Peel Ripening of Harvested Banana under Natural Condition
Previous Article in Journal
siRNA-Mediated Simultaneous Regulation of the Cellular Innate Immune Response and Human Respiratory Syncytial Virus Replication
 
 
Article

Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses

1
SGIT-INIA, 28040 Madrid, Spain
2
Faculty of Veterinary Medicine, Universidad Complutense de Madrid (UCM), Ciudad Universitaria s/n, 28040 Madrid, Spain
3
School of Veterinary Medicine and Zootechnics, Faculty of Agricultural Sciences, University of Cuenca, 010220 Cuenca, Ecuador
*
Author to whom correspondence should be addressed.
Biomolecules 2019, 9(5), 166; https://doi.org/10.3390/biom9050166
Received: 15 March 2019 / Revised: 20 April 2019 / Accepted: 23 April 2019 / Published: 29 April 2019
Metformin is an anti-hyperglycemic drug widely used for the treatment of insulin resistance and glucose intolerance and is currently considered for preventing large-for-gestational-age (LGA) offspring in pregnant women affected by obesity or diabetes. Our hypothesis was the opposite—metformin may be used for improving the development of offspring affected by intrauterine growth restriction (IUGR) and preventing the appearance of small-for-gestational-age (SGA) neonates in non-obese and non-diabetic but malnourished pregnancies. The current study, performed in a swine preclinical model of IUGR by undernutrition, showed that fetuses in the treated group showed no significant increases in body-weight, but showed a significantly higher weight of the brain, the total thoracic and abdominal viscera, the liver, the kidneys, the spleen, and the adrenal glands. Maternal metformin treatment was also related to significant increases in the fetal plasma concentration of parameters indicative of glycemic (glucose and fructosamine) and lipid profiles (triglycerides). Overall, these results suggest a protective effect of the treatment on the developmental competence of the fetuses. These findings may be of high value for human medicine in case of maternal malnutrition, since metformin is a cheap drug easily available, but also in case of placental deficiency, since metformin seems to improve placental development and function. View Full-Text
Keywords: intrauterine-growth-restriction; metformin; pregnancy; swine-model intrauterine-growth-restriction; metformin; pregnancy; swine-model
Show Figures

Figure 1

MDPI and ACS Style

Garcia-Contreras, C.; Vazquez-Gomez, M.; Pesantez-Pacheco, J.L.; Torres-Rovira, L.; Heras-Molina, A.; Encinas, T.; Astiz, S.; Gonzalez-Bulnes, A. Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses. Biomolecules 2019, 9, 166. https://doi.org/10.3390/biom9050166

AMA Style

Garcia-Contreras C, Vazquez-Gomez M, Pesantez-Pacheco JL, Torres-Rovira L, Heras-Molina A, Encinas T, Astiz S, Gonzalez-Bulnes A. Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses. Biomolecules. 2019; 9(5):166. https://doi.org/10.3390/biom9050166

Chicago/Turabian Style

Garcia-Contreras, Consolación, Marta Vazquez-Gomez, José Luis Pesantez-Pacheco, Laura Torres-Rovira, Ana Heras-Molina, Teresa Encinas, Susana Astiz, and Antonio Gonzalez-Bulnes. 2019. "Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses" Biomolecules 9, no. 5: 166. https://doi.org/10.3390/biom9050166

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop